The cell therapy bioprocessing market has been analyzed on the basis of technology, cell type, end user, and region. The market based on region is segmented into North America, Europe, Asia Pacific, the Middle East and Africa, and South and Central America. The report emphasizes on parameters such as market trends, technological advancements, market dynamics, and leading company’s competitive landscape analysis to offers insights and in-depth analysis of the cell therapy bioprocessing market. It also includes the analysis of COVID-19 pandemic across the market in all the key regions.
Cell therapies have shown positive results in treating various chronic diseases including rare genetic disorders by offering regenerative medicines and personalized medicines. Increasing need of treating chronic diseases have pushed the research and development activities resulting in growing cell therapy production and product approvals. Few instances are listed below for the cell therapies approvals that have contributed to the growth of the cell therapy bioprocessing market.
Thus, growing product developments have resulted in various product approvals that reflects the increase in cell therapies. Therefore, it is expected that the growing approvals for cell therapies are enormously increasing the cell therapy bioprocessing, which, in turn is likely to drive the market’s growth over the coming years
The cell therapy bioprocessing market, by technology, is segmented into bioreactor, lyophilization, electro spinning, controlflow centrifugation, ultrasonic lysis, genome editing technology, cell immortalization technology, and viral vector technology. The Bioreactor segment held the largest share of the market in 2020, whereas the genome editing technology segment is anticipated to register the highest CAGR of 14.5% in the market during the forecast period.
The cell therapy bioprocessing market, by cell type, is segmented into stem cell, immune cell, human embryonic stem cell, pluripotent stem cell, hematopoietic stem cells. The stem cell segment held the largest share of the market in 2020, whereas the same segment is anticipated to register the highest CAGR of 14.0% in the market during the forecast period.
The cell therapy bioprocessing market, by indication, is segmented cardiovascular disease (CVD), oncology, wound healing, orthopedic, and others. The oncology segment held the largest share of the market in 2020, and the orthopedic segment is anticipated to register the highest CAGR of 14.3% in the market during the forecast period.
Companies operating in the cell therapy bioprocessing market are adopting organic strategies such as product launches and expansions to expand their footprint and product portfolio worldwide as well as to address the growing demands.
The regional trends and factors influencing the Cell Therapy Bioprocessing Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Cell Therapy Bioprocessing Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2020 | US$ 11.19 Billion |
| Market Size by 2028 | US$ 30.05 Billion |
| Global CAGR (2020 - 2028) | 13.5% |
| Historical Data | 2018-2019 |
| Forecast period | 2021-2028 |
| Segments Covered |
By Product Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Cell Therapy Bioprocessing Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Cell Therapy Bioprocessing Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The List of Companies - Cell Therapy Bioprocessing Market
The costs of the Cell Therapy Bioprocessing are much higher, and they may cost US$ 50,000–100,000, or more, per cell therapy. The cost may also differ from product to product types.
Key factors driving the growth of the market are increasing investments for cell and gene therapy manufacturing, and growing approvals for cell therapies are the major factors driving the market growth. However, challenges such as high cost of product, regulatory challenges, and logistics challenges are likely to hinder the growth of the cell therapy bioprocessing market.
Cell therapy bioprocessing is a subfield of bioprocess engineering that bridges cell therapy and bioprocessing (i.e., biopharmaceutical manufacturing). Cell therapy is one of the fastest-growing areas of the life sciences. It entails delivering entire living cells to a patient to treat disease.